- Conditions
- Preeclampsia
- Interventions
- Apheresis using Liposorber LA-15 System
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 658
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pyoderma Gangrenosum
- Interventions
- Ixekizumab
- Biological
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Gahanna, Ohio
- Conditions
- Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant, Pleural Effusions, Malignant, Mesothelin (Msln)
- Interventions
- Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin
- Procedure · Drug · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hurthle Cell Thyroid Cancer, Tall Cell Variant Thyroid Cancer, Follicular Thyroid Cancer, Thyroid Cancer, Papillary Thyroid Cancer
- Interventions
- 68-Gallium Dotatate
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Months to 98 Years
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1977
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Glargine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Patient Lying, Privacy Statements, Risk Statements, Benefit Statements, Patient Lie Detection
- Interventions
- Benefit statement, Risk Statement, Privacy Statement, Benefit + Privacy, Risk + Privacy
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 619 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Provo, Utah
- Conditions
- DCIS, Stage 0 Breast Cancer, Ductal Breast Carcinoma In Situ
- Interventions
- Treatment recommendation surveys, 7-gene biosignature
- Other · Device
- Lead sponsor
- PreludeDx
- Industry
- Eligibility
- 30 Years to 85 Years · Female only
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2036
- U.S. locations
- 30
- States / cities
- Scottsdale, Arizona • La Jolla, California • San Mateo, California + 25 more
- Conditions
- Retinoblastoma
- Interventions
- vincristine, topotecan, filgrastim, PEG-filgrastim, carboplatin, focal therapy, etoposide, cyclophosphamide, MESNA, doxorubicin, enucleation, external beam radiation or proton beam radiation
- Drug · Other · Procedure + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Sleep Problems, Sleep Hygiene
- Interventions
- Good Nights Sleep Program
- Behavioral
- Lead sponsor
- Auburn University
- Other
- Eligibility
- 7 Years to 10 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Auburn, Alabama
- Conditions
- Racial/Ethnic Minorities on Dialysis
- Interventions
- Active Comparator: peer navigator, Placebo Comparator: Control Arm (standard of care)
- Behavioral · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Disability Physical
- Interventions
- CAPABLE
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 268 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Thyroid Cancer
- Interventions
- Vemurafenib (All Groups), Vemurafenib (Post Surgery) - Group A + C, Post Surgery - Group B
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer, Health Behavior
- Interventions
- Prostate Cancer Genius App, US Prevention Taskforce App
- Behavioral
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 45 Years to 69 Years · Male only
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
- Interventions
- Alpha-type-1 Polarized Dendritic Cells, Biopsy, Computed Tomography, Leukapheresis, Pembrolizumab, Quality-of-Life Assessment
- Biological · Procedure · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Marijuana Use
- Interventions
- 1) Face-to-face, and 2) Computer-mediated motivational type interviews
- Behavioral
- Lead sponsor
- University of Texas, El Paso
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- Tumors
- Interventions
- Mirvetuximab soravtansine
- Drug
- Lead sponsor
- ImmunoGen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 10
- States / cities
- Fairway, Kansas • Boston, Massachusetts • Detroit, Michigan + 6 more
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Computed Tomography, Gallium Ga 68-HA-DOTA-TATE, Positron Emission Tomography
- Procedure · Radiation
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Other Cancer
- Interventions
- Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application, Digital application with expert guidelines on lifestyle modification
- Behavioral
- Lead sponsor
- Complement Theory Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Dover, Delaware
- Conditions
- End-stage Renal Disease
- Interventions
- PROPATEN, Standard Graft
- Device
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • New Orleans, Louisiana • Cleveland, Ohio + 1 more
- Conditions
- Chronic Pain
- Interventions
- Behavior Change Coaching, Nutrition, Autonomic Recalibration, Dry Needling, Osteopathic Manipulative Treatment, Counseling Psychology, Multiple Treatments
- Behavioral · Other · Procedure
- Lead sponsor
- Edward Via Virginia College of Osteopathic Medicine
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Auburn, Alabama
- Conditions
- Obesity, Diabetes
- Interventions
- TSSC, TSSC Randomized Behavioral Intervention for weight loss
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3,100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Brownsville, Texas
- Conditions
- Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Interventions
- belinostat, carboplatin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 81
- States / cities
- Hartford, Connecticut • New Britain, Connecticut • Lewes, Delaware + 53 more
- Conditions
- Advanced/Metastatic Tumors
- Interventions
- Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 5 more
- Conditions
- Rheumatoid Arthritis, Myositis, Osteoarthritis, Weakness, Muscle
- Interventions
- Strength Training
- Other
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana